Volume | 478,470 |
|
|||||
News | - | ||||||
Day High | 5.02 | Low High |
|||||
Day Low | 4.70 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Capricor Therapeutics Inc | CAPR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
4.90 | 4.70 | 5.02 | 4.82 | 4.94 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
5,102 | 478,470 | $ 4.84 | $ 2,313,573 | - | 2.68 - 8.2212 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:39:52 | 1 | $ 4.80 | USD |
Capricor Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
151.35M | 31.40M | - | 25.18M | -22.29M | -0.71 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Capricor Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CAPR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 5.77 | 6.05 | 4.685 | 5.23 | 481,286 | -1.03 | -17.85% |
1 Month | 6.66 | 7.28 | 4.685 | 6.03 | 322,640 | -1.92 | -28.83% |
3 Months | 4.07 | 7.28 | 3.56 | 5.63 | 299,195 | 0.67 | 16.46% |
6 Months | 2.76 | 7.28 | 2.68 | 4.81 | 266,353 | 1.98 | 71.74% |
1 Year | 4.13 | 8.2212 | 2.68 | 4.73 | 211,768 | 0.61 | 14.77% |
3 Years | 3.99 | 8.2212 | 2.56 | 4.56 | 265,077 | 0.75 | 18.80% |
5 Years | 0.512 | 12.32 | 0.2526 | 5.92 | 756,008 | 4.23 | 825.78% |
Capricor Therapeutics Description
Capricor Therapeutics, Inc. is a San Diego based biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in late-stage clinical development for treating Duchenne muscular dystrophy (DMD). Capricor is also developing its exosome technology as a next-generation therapeutic platform. Capricor's proprietary StealthX¿ exosome platform has potential for a broad range of new therapeutic applications in the field of vaccinology as well as targeted oligonucleotide, protein and small molecule therapeutics to treat or prevent a variety of diseases. |